Global Short Bowel Syndrome SBS Drugs Market Size By Type (Glucagon-Like Peptide-2 (GLP-2), Growth Hormone), By Application (Hospitals, Clinics), By Region, And Segment Forecasts, 2023 to 2032

The Global Short Bowel Syndrome (SBS) Drugs Market was valued at USD 814 million in 2023 and is projected to reach USD 1.51 billion by 2031, growing at a CAGR of 7.9% during the forecast period from 2023 to 2031. The rising prevalence of gastrointestinal disorders, increasing awareness of SBS treatment options, and advancements in pharmacological therapy are driving the market forward. Short Bowel Syndrome is a rare but serious condition often requiring long-term parenteral nutrition or specialized drug treatment, with Teduglutide being one of the most prescribed therapies globally.

Drivers:

1. Increasing Incidence of Gastrointestinal Diseases:

The growing number of gastrointestinal surgeries, Crohn’s disease cases, and congenital bowel disorders contributes to the rising occurrence of SBS, fueling the demand for targeted pharmaceutical treatments.

2. Advancements in Drug Development:

New drug formulations, including GLP-2 analogs and pipeline biologics, are enhancing treatment outcomes for SBS patients. Ongoing R&D activities and regulatory approvals of innovative therapies support market growth.

3. Rising Awareness and Diagnosis:

Efforts by healthcare organizations and support groups have improved SBS awareness, facilitating early diagnosis and access to drug-based management strategies.

Restraints:

1. High Treatment Costs:

SBS drug therapies, particularly branded biologics, can be prohibitively expensive, limiting access in low-income regions and posing reimbursement challenges in cost-sensitive markets.

2. Limited Patient Population:

As a rare disorder, the relatively small patient base limits the market’s expansion potential and deters broader pharmaceutical investment compared to more common chronic diseases.

Opportunity:

1. Emerging Markets Expansion:

Rapidly developing healthcare infrastructure in Asia-Pacific and Latin America is creating opportunities for SBS drug penetration. Increased investment in rare disease management in these regions is a notable growth lever.

2. Innovation in Personalized Treatment:

Precision medicine and patient-specific drug formulations for SBS are opening new frontiers. Biopharmaceutical companies are exploring combinations of hormone analogs and microbiota therapies tailored to individual patient needs.

Market by Drug Type Insights:

The GLP-2 analogs segment, led by Teduglutide, dominated the SBS drugs market in 2023. Teduglutide significantly enhances intestinal absorption, reducing the need for parenteral support. This segment is expected to continue its dominance due to proven clinical outcomes and increasing adoption in developed healthcare systems.

Other emerging drug categories such as somatostatin analogs and bile acid sequestrants are gaining traction, particularly in adjunct therapy settings, but remain secondary to GLP-2 analogs in terms of market share.

Market by End-use Insights:

In 2023, the hospital pharmacies segment accounted for the largest share of the SBS drugs market due to the necessity of supervised and regulated treatment settings. Hospital-based care ensures patient monitoring and effective parenteral drug administration. However, retail pharmacies and specialty clinics are anticipated to witness growth as oral formulations and home-based care gain momentum in SBS treatment protocols.

Market by Regional Insights:

North America led the SBS drugs market in 2023, driven by high healthcare expenditure, established reimbursement frameworks, and the presence of key pharmaceutical players. The region benefits from favorable regulatory environments and greater access to orphan drugs.

Asia-Pacific is projected to experience the fastest growth through 2031, due to improved diagnostic facilities, growing awareness of rare diseases, and increasing government funding for healthcare infrastructure in countries like China and India.

Competitive Scenario:

Key players in the SBS drugs market include Takeda Pharmaceutical Company Limited, VectivBio AG, 9 Meters Biopharma, Zealand Pharma A/S, and Hanmi Pharmaceutical Co., Ltd. These companies are focusing on expanding drug indications, launching patient support programs, and engaging in strategic collaborations.

Key Developments:

2023: Takeda’s Teduglutide received additional indication expansion approval in Europe for pediatric patients with SBS.

2024: VectivBio initiated a Phase III clinical trial for apraglutide in multiple international markets.

2025: Zealand Pharma announced promising Phase II data for glepaglutide, a novel long-acting GLP-2 analog for SBS management.

Scope of Work – Global Short Bowel Syndrome (SBS) Drugs Market

FAQs:

1) What is the current market size of the Global Short Bowel Syndrome (SBS) Drugs Market?

The market size was USD 814 million in 2023.

2) What is the major growth driver of the Global Short Bowel Syndrome (SBS) Drugs Market?

The increasing prevalence of gastrointestinal surgeries and Crohn’s disease, leading to SBS cases, is a key growth driver.

3) Which is the largest region during the forecast period in the Global Short Bowel Syndrome (SBS) Drugs Market?

North America is the largest region due to advanced healthcare infrastructure and accessibility to orphan drug therapies.

4) Which segment accounted for the largest market share in the Global Short Bowel Syndrome (SBS) Drugs Market?

The GLP-2 analog segment led the market in 2023, driven by the success of Teduglutide.

5) Who are the key market players in the Global Short Bowel Syndrome (SBS) Drugs Market?

Major players include Takeda Pharmaceutical, VectivBio AG, 9 Meters Biopharma, Zealand Pharma A/S, and Hanmi Pharmaceutical.

Let me know if you'd like this report exported to Word or PDF format.